A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Public ClinicalTrials.gov record NCT05020236. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
Study identification
- NCT ID
- NCT05020236
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 944 participants
Conditions and interventions
Conditions
Interventions
- Daratumumab Drug
- Dexamethasone Drug
- Elranatamab Drug
- Pomalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 3, 2021
- Primary completion
- Apr 26, 2026
- Completion
- May 30, 2027
- Last update posted
- May 4, 2026
2021 โ 2027
United States locations
- U.S. sites
- 11
- U.S. states
- 4
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clovis Community Medical Center | Clovis | California | 93611 | Active, not recruiting |
| Community Regional Medical Center | Fresno | California | 93721 | Active, not recruiting |
| UCHealth Poudre Valley Hospital | Fort Collins | Colorado | 80524 | Active, not recruiting |
| UCHealth Greeley Hospital | Greeley | Colorado | 80634 | Active, not recruiting |
| Sylvester Comprehensive Cancer Center - Aventura | Aventura | Florida | 33180 | Recruiting |
| Sylvester Comprehensive Cancer Center - Coral Springs | Coral Springs | Florida | 33065 | Recruiting |
| University of Miami Hospital and Clinics - Deerfield Beach | Deerfield Beach | Florida | 33442 | Recruiting |
| Sylvester Comprehensive Cancer Center - Hollywood | Hollywood | Florida | 33021 | Recruiting |
| University of Miami Hospital and Clinics | Miami | Florida | 33136 | Recruiting |
| Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). | New York | New York | 10021 | Recruiting |
| Memorial Sloan Kettering Cancer Center - Main Campus | New York | New York | 10065 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05020236, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 ยท Synced May 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05020236 live on ClinicalTrials.gov.